{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:10:39Z","timestamp":1791846639898,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.lungcan.2019.04.027","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T19:04:45Z","timestamp":1556737485000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2865-659X","authenticated-orcid":false,"given":"Barbara","family":"Melosky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Florescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Rothenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Laurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wheatley-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenwood","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Neil","family":"Reaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Butts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevin","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Card","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-2673","authenticated-orcid":false,"given":"Jenny","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normand","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Brown-Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Kaurah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M.","family":"Prentice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2019.04.027_bib0005","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA: Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.lungcan.2019.04.027_bib0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cllc.2017.05.019","article-title":"An evolving algorithm to select and sequence therapies in EGFR mutation-positive NSCLC: A strategic approach","volume":"19","author":"Melosky","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2019.04.027_bib0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40425-018-0382-2","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)","volume":"6","author":"Brahmer","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2019.04.027_bib0020","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.lungcan.2014.07.005","article-title":"Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: a cross-trial comparison of two phase III trials","volume":"85","author":"Scagliotti","year":"2014","journal-title":"Lung Cancer"},{"issue":"9699","key":"10.1016\/j.lungcan.2019.04.027_bib0025","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2019.04.027_bib0030","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2019.04.027_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.12.001","article-title":"Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK","volume":"53","author":"Martinelli","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2019.04.027_bib0040","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.lungcan.2019.04.027_bib0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-010-1323-z","article-title":"Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice","volume":"67","author":"Denton","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2019.04.027_bib0050","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","article-title":"The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer","volume":"16","author":"Banerji","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.04.027_bib0055","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/1535-7163.MCT-07-0231","volume":"6","author":"Davies","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2019.04.027_bib0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","article-title":"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study","volume":"14","author":"Janne","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2019.04.027_bib0065","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial","volume":"317","author":"Janne","year":"2017","journal-title":"Jama"},{"key":"10.1016\/j.lungcan.2019.04.027_bib0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1755-8794-3-26","article-title":"A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors","volume":"3","author":"Loboda","year":"2010","journal-title":"BMC Med. Genom."},{"key":"10.1016\/j.lungcan.2019.04.027_bib0075","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-09-1577","article-title":"Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)","volume":"70","author":"Dry","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2019.04.027_bib0080","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1158\/1078-0432.CCR-16-0021","article-title":"Clinically viable gene expression assays with potential for predicting benefit from MEK inhibitors","volume":"23","author":"Brant","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.04.027_bib0085","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/bjc.2012.8","article-title":"The MEK1\/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models","volume":"106","author":"Holt","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2019.04.027_bib0090","article-title":"Canadian Cancer Trials Group (CCTG) IND215: a phase Ib study of selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens","author":"Goffin","year":"2018","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.lungcan.2019.04.027_bib0095","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/annonc\/mdx628","article-title":"SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer","volume":"28","author":"Soria","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2019.04.027_bib0100","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1002\/cncr.24596","article-title":"Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials","volume":"115","author":"Hicks","year":"2009","journal-title":"Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219304283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219304283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T21:38:35Z","timestamp":1565127515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219304283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":20,"alternative-id":["S0169500219304283"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.04.027","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}